{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:51:17Z","timestamp":1794585077965,"version":"4.9.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Transfusion-dependent \u03b2-thalassemia (TDT) can have negative impacts on a patient\u2019s health-related quality of life (HRQoL). Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo CRISPR-Cas9 gene\u2013edited cell therapy for TDT shown in a phase 3 clinical trial to result in transfusion independence in most participants. Here, we describe changes in patient-reported outcome (PRO) measures after exa-cel infusion in 54 participants (adults, n = 35; adolescents, n = 19), who had \u226516 months of follow-up. In adults, PRO measures included the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) and the Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT). In adolescents, the EuroQol Quality of Life Scale-5 dimensions-youth (EQ-5D-Y) and Pediatric Quality of Life Inventory (PedsQL) instruments were used. At baseline, mean EQ-5D-5L visual analog scale (VAS) and US and UK health utility index scores in adults were in line with baseline scores reported for adults with TDT. After exa-cel infusion, all 3 scores improved, exceeding established minimal clinically important differences (MCIDs) at month 48. Mean FACT-General (FACT-G) score and bone marrow transplant subscale score improved through month 48, also exceeding MCIDs, with improvements in all 4 FACT-G subscales (physical, social\/family, emotional, and functional well-being). Consistent with HRQoL improvements in adults, adolescents had increases from baseline at month 24 in mean EQ-5D-Y VAS score and PedsQL total score, with sustained improvements in both physical and psychosocial health subcomponents. These results indicate exa-cel leads to broad, durable, and clinically meaningful improvements in HRQoL in adults and adolescents with TDT. These trials were registered at www.ClinicalTrials.gov as #NCT03655678 and #NCT04208529.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016702","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:47:09Z","timestamp":1756302429000},"page":"6502-6510","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Improvements in health-related quality of life in patients with transfusion-dependent \u03b2-thalassemia after exagamglogene autotemcel"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0974-1249","authenticated-orcid":false,"given":"Josu","family":"de la Fuente","sequence":"first","affiliation":[{"name":"1Departments of Pediatrics and Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydar","family":"Frangoul","sequence":"additional","affiliation":[{"name":"2Pediatric Hematology\/Oncology, Sarah Cannon Research Institute at the Children\u2019s Hospital at TriStar Centennial, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[{"name":"3Department for Hematology\/Oncology, University of T\u00fcbingen, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site T\u00fcbingen, T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5442-5536","authenticated-orcid":false,"given":"Donna","family":"Wall","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, The Hospital for Sick Children\/University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[{"name":"5Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1070-8486","authenticated-orcid":false,"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8099-9501","authenticated-orcid":false,"given":"Amanda M.","family":"Li","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, BC Children\u2019s Hospital, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami J.","family":"Shah","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology\/Stem Cell Transplantation and Regenerative Medicine and Department of Pediatrics, Lucile Packard Children\u2019s Hospital, Stanford School of Medicine, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-0799","authenticated-orcid":false,"given":"Ben","family":"Carpenter","sequence":"additional","affiliation":[{"name":"9Department of Hematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L.","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Children\u2019s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, Department of Medicine, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-3749","authenticated-orcid":false,"given":"Robert I.","family":"Liem","sequence":"additional","affiliation":[{"name":"12Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Rupprecht","sequence":"additional","affiliation":[{"name":"13Department of General Pediatrics, Hematology\/Oncology, University Children\u2019s Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-9238","authenticated-orcid":false,"given":"Kevin H.M.","family":"Kuo","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1964-7746","authenticated-orcid":false,"given":"Hayley","family":"Merkeley","sequence":"additional","affiliation":[{"name":"15Division of Hematology, The University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Algeri","sequence":"additional","affiliation":[{"name":"16IRCCS, Ospedale Pediatrico Bambino Ges\u00f9 Rome, Department of Health Sciences, Magna Graecia University, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-5367","authenticated-orcid":false,"given":"Wally","family":"Smith","sequence":"additional","affiliation":[{"name":"17Division of General Internal Medicine, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Kohli","sequence":"additional","affiliation":[{"name":"18Vertex Pharmaceuticals Incorporated, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[{"name":"18Vertex Pharmaceuticals Incorporated, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Rubin","sequence":"additional","affiliation":[{"name":"18Vertex Pharmaceuticals Incorporated, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"18Vertex Pharmaceuticals Incorporated, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hobbs","sequence":"additional","affiliation":[{"name":"18Vertex Pharmaceuticals Incorporated, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"19Department of Pediatric Hematology and Oncology, IRCCS, Ospedale Pediatrico Bambino Ges\u00f9 Rome, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2025122308311411200_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2025122308311411200_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/gim.2016.173","article-title":"\u03b2-Thalassemia","volume":"19","author":"Origa","year":"2017","journal-title":"Genet Med"},{"issue":"6","key":"2025122308311411200_bib3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"key":"2025122308311411200_bib4","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in beta-thalassemia","volume":"37","author":"Shah","year":"2019","journal-title":"Blood Rev"},{"issue":"10116","key":"2025122308311411200_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"2025122308311411200_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.blre.2018.02.001","article-title":"A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies?","volume":"32","author":"Cappellini","year":"2018","journal-title":"Blood Rev"},{"issue":"10","key":"2025122308311411200_bib7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17474086.2021.1977116","article-title":"Improving outcomes and quality of life for patients with transfusion-dependent beta-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies","volume":"14","author":"Taher","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2025122308311411200_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jha2.282","article-title":"Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent beta-thalassaemia in the United Kingdom: a mixed methods observational study","volume":"2","author":"Shah","year":"2021","journal-title":"EJHaem"},{"key":"2025122308311411200_bib9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/PPA.S269352","article-title":"Promoting adherence to iron chelation treatment in beta-thalassemia patients","volume":"16","author":"Eziefula","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"2025122308311411200_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40271-024-00678-7","article-title":"Health-related quality-of-life impacts associated with transfusion-dependent \u03b2-thalassemia in the USA and UK: a qualitative assessment","volume":"17","author":"Drahos","year":"2024","journal-title":"Patient"},{"issue":"2","key":"2025122308311411200_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40271-020-00473-0","article-title":"Patient- and caregiver-reported burden of transfusion-dependent \u03b2-thalassemia measured using a digital application","volume":"14","author":"Paramore","year":"2021","journal-title":"Patient"},{"key":"2025122308311411200_bib12","doi-asserted-by":"crossref","first-page":"2849163","DOI":"10.1155\/2021\/2849163","article-title":"Quality of life and related paraclinical factors in Iranian patients with transfusion-dependent thalassemia","volume":"2021","author":"Khodashenas","year":"2021","journal-title":"J Environ Public Health"},{"issue":"2","key":"2025122308311411200_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2019.12.003","article-title":"Systematic literature review of the burden of disease and treatment for transfusion-dependent \u03b2-thalassemia","volume":"42","author":"Betts","year":"2020","journal-title":"Clin Ther"},{"issue":"1","key":"2025122308311411200_bib14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/asheducation-2017.1.278","article-title":"New therapeutic targets in transfusion-dependent and -independent thalassemia","volume":"2017","author":"Cappellini","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"2025122308311411200_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025122308311411200_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"2025122308311411200_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.07650.x","article-title":"Discovering the genetics underlying foetal haemoglobin production in adults","volume":"145","author":"Thein","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2025122308311411200_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood-2011-09-382408","article-title":"Fetal hemoglobin levels and morbidity in untransfused patients with beta-thalassemia intermedia","volume":"119","author":"Musallam","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2025122308311411200_bib19","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood-2009-04-217901","article-title":"Amelioration of Sardinian beta0 thalassemia by genetic modifiers","volume":"114","author":"Galanello","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2025122308311411200_bib20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent beta-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2025122308311411200_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2025122308311411200_bib22","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jama.2014.13128","article-title":"Minimal clinically important difference: defining what really matters to patients","volume":"312","author":"McGlothlin","year":"2014","journal-title":"JAMA"},{"key":"2025122308311411200_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"2025122308311411200_bib24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jval.2020.03.003","article-title":"Estimation of an instrument-defined minimally important difference in EQ-5D-5L index scores based on scoring algorithms derived using the EQ-VT version 2 valuation protocols","volume":"23","author":"Henry","year":"2020","journal-title":"Value Health"},{"issue":"4","key":"2025122308311411200_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2025122308311411200_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","author":"Varni","year":"2003","journal-title":"Ambul Pediatr"},{"issue":"10","key":"2025122308311411200_bib27","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"3","key":"2025122308311411200_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol","year":"1990","journal-title":"Health Policy"},{"issue":"6","key":"2025122308311411200_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","article-title":"A comparison of the EQ-5D-3L and EQ-5D-5L","volume":"38","author":"Thompson","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2025122308311411200_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"O'Hara","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2025122308311411200_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12955-024-02265-8","article-title":"Appropriateness of the EQ-5D-5L in capturing health-related quality of life in individuals with transfusion-dependent beta-thalassemia: a mixed methods study","volume":"22","author":"Boateng-Kuffour","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2025122308311411200_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Med Care"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6502\/2475209\/blooda_adv-2025-016702-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6502\/2475209\/blooda_adv-2025-016702-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:31:19Z","timestamp":1766496679000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6502\/546757\/Improvements-in-health-related-quality-of-life-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":32,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016702","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,12]]}}}